Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

被引：151

作者：

Courreges, J. -P. ^{[1
]}

Vilsboll, T. ^{[2
]}

Zdravkovic, M. ^{[3
]}

Le-Thi, T. ^{[3
]}

Krarup, T. ^{[2
]}

Schmitz, O. ^{[4
]}

Verhoeven, R. ^{[5
]}

Buganova, I. ^{[6
]}

Madsbad, S. ^{[7
]}

机构：

[1] Ctr Hosp Narbonne, Narbonne, France

[2] Gentofte Univ Hosp, Hellerup, Denmark

[3] Novo Nordisk, Bagsvaerd, Denmark

[4] Arhus Hosp, Aarhus, Denmark

[5] Gelre Ziekenhuis, Apeldoorn, Netherlands

[6] Dibetol Ambulancia, Zilina, Slovakia

[7] Univ Copenhagen, Hvidovre Hosp, DK-2650 Hvidovre, Denmark

来源：

DIABETIC MEDICINE | 2008年 / 25卷 / 09期

关键词：

D O I：

10.1111/j.1464-5491.2008.02484.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1129 / 1131

页数：3

共 6 条

[1] Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
Gæde, P
Hildebrandt, P
Hess, G
Parving, HH
Pedersen, O
[J]. DIABETOLOGIA, 2005, 48 (01) : 156 - 163
[2] The metabolic syndrome: Inflammation, diabetes mellitus, and cardiovascular disease
Haffner, SM
[J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (2A) : 3A - 11A
[3] Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Nyström, T
Gutniak, MK
Zhang, QM
Zhang, F
Holst, JJ
Ahrén, B
Sjöholm, Å
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2004, 287 (06): : E1209 - E1215
[4] Thrainsdottir Inga, 2004, Diab Vasc Dis Res, V1, P40, DOI 10.3132/dvdr.2004.005
[5] Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
Vilsboll, T.
Brock, B.
Perrild, H.
Levin, K.
Lervang, H. -H.
Kolendorf, K.
Krarup, T.
Schmitz, O.
Zdravkovic, M.
Le-Thi, T.
Madsbad, S.
[J]. DIABETIC MEDICINE, 2008, 25 (02) : 152 - 156
[6] Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Vilsboll, Tina
Zdravkovic, Milan
Le-Thi, Tu
Krarup, Thure
Schmitz, Ole
Courreges, Jean-Pierre
Verhoeven, Robert
Buganova, Ingrid
Madsbad, Sten
[J]. DIABETES CARE, 2007, 30 (06) : 1608 - 1610

← 1 →